To prevent chronic liver inflammation from leading to HCC, the use of particular NRF2 inhibitors may be preferable to the use of antioxidants and NRF2 activators as cancer-preventive drugs [33]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.